Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple antithrombotic therapy with aspirin, clopidogrel, and rivaroxaban in STEMI with large thrombus burden
IRCT20120215009014N612Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin, clopidogrel and rivaroxaban in myocardial infarction (MI) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Need for stenting, Stent size and 3 more. Started Jun 2026; status: completed.
02
Drugs
aspirinclopidogrelrivaroxaban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20120215009014N612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N612.